Advanced Therapy
With a well-documented safety profile and broad engineering potential, Adenoviruses are driving the future of precision medicine. At ReIGNITE, we are developing a helper-independent "gutless" adenovirus platform for both oncology and non-oncology indications. Their unique characteristics—including targeted delivery, a robust immune response, and the ability to carry large genetic payloads—make them ideal for next-generation therapies.
Adenoviruses can deliver genetic payloads of up to 36 kilobases—far exceeding many other viral vectors.
Adenoviruses can be engineered with cell-specific tropism. This precision enhances therapeutic impact and reduces the risk of off-target effects.
Adenoviruses elicit a strong immune response against tumor cells. This dual mechanism not only destroys cancer cells directly but also primes the immune system to recognize and eliminate residual cancer.
.png)
Adenoviruses do not integrate into the genome of host cell DNA, ensuring their genetic material does not disrupt the host genome. This feature contributes to their well-established safety profile.
Adenoviruses are capable of infecting a wide range of cell types, making them applicable across both oncology and non-oncology indications
Adenoviruses have been extensively studied in clinical settings, with a strong history of safe administration.
Targeting Cancer
Adenoviruses offer an exceptional balance of safety, versatility, and genetic capacity, enabling the development of highly targeted and effective treatments for a range of indications.
Through directed evolution, adenoviruses are engineered to recognize and infect specific cells with high specificity while sparing healthy tissues.
Our high-capacity adenoviruses are devoid of viral genes, making them ideal delivery vehicles to targeting genetic diseases
Adenoviruses are capable of carry large payloads (up to 36 kB). This enables the inclusion of multiple therapeutic genes in a single treatment, enhancing the overall efficacy of gene therapy.
Adenoviruses are optimized for safety by reducing their interaction with non-target tissues and ensuring their non-integrating nature. This makes them more suitable for repeated dosing in clinical settings.
Identifying adenovirus variants with enhanced ability to circulate and distribute systemically, ensuring efficient delivery to the organs, tissues, and cells of interest.
